Treatment of Inflammatory Bowel Disease with Biologics

147

CD/UC

Bortlik et al. [83]

CD: 61UC: 17

Prospective observational (77% of CD and 59% of UC with concomitant IMM)

CD: 18% (0.5 year), 41% (1 year), 49% (2 years)

Non-colonic location for CD, previous anti-TNF-

α^

treatment, previous surgery

Type of anti-TNF-

α agent,

smoking status, disease behavior, corticosteroid therapy within 1 year before biologics withdrawal, concomitant IMM, CRP level, fecal calprotectin, anti-TNF-

α trough levels at

the time of anti-TNF-

α^

withdrawal

82%

UC: 23% (0.6 year), 23% (1 year), 36% (2 years)

Dai et al. [

49

]

CD: 109

Prospective observational

CD: 21% (1 year)

Nil

Clinical remission, mucosal healing, gender, disease duration, smoking status, history of appendicectomy, location, behavior, extraintestinal manifestations, previous surgery, previous biological therapy, CRP level, effect of induction therapy

CD: 78.3%

UC: 107

(31% concomitant IMM)

UC: 14% (1 year)

UC: 66.7%

Hlavaty et al. [^84

]

CD:17

Prospective observational

Cohorts with deep remission, 18% (0.5 year), 27% (1 year)

Male

Type of IBD, age, disease duration, CD location, behavior, smoking status, previous surgery, type and duration of anti-TNF-

α agent,

concomitant azathioprine, fecal calprotectin, CRP, hemoglobin

100%

(36% with concomitant IMM for cohorts in clinical remission)(64% with concomitant IMM for cohorts in deep remission)

UC: 5

Cohorts with clinical remission, 18% (0.5 year), 27% (1 year)

(continued)

10 Cessation offlBiologics: Can It BeflDone?